2025 China Anti-Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 China Anti-Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-migraine drugs market in China include AbbVie (Allergan), Eli Lilly, Amgen, and Teva Pharmaceutical Industries Ltd. AbbVie, through Allergan, offers products like Botox for preventive migraine treatment and anti-CGRP monoclonal antibodies. Eli Lilly has a strong portfolio including both acute and preventive migraine therapies and is a key player in China’s growing migraine drug market. Amgen is notable for its presence through anti-CGRP therapies such as Aimovig (erenumab), targeting migraine prevention. Teva Pharmaceutical made significant progress in China with AJOVY (fremanezumab), demonstrating efficacy in reducing migraine days, including Phase 3 trial success in the Chinese population.
These companies leverage innovative therapies responding to China's large migraine population, estimated at 65 million, which drives demand. Teva is expanding indications for AJOVY to pediatric use, while AbbVie and Amgen continue to lead with anti-CGRP monoclonal antibodies and Botox. Despite the large patient base, migraine treatment in China often involves NSAIDs due to accessibility and cost, with triptans less used compared to Western countries, highlighting an unmet need for advanced therapies that these multinational companies address with their novel drug launches and clinical progress.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-migraine drugs market in China include AbbVie (Allergan), Eli Lilly, Amgen, and Teva Pharmaceutical Industries Ltd. AbbVie, through Allergan, offers products like Botox for preventive migraine treatment and anti-CGRP monoclonal antibodies. Eli Lilly has a strong portfolio including both acute and preventive migraine therapies and is a key player in China’s growing migraine drug market. Amgen is notable for its presence through anti-CGRP therapies such as Aimovig (erenumab), targeting migraine prevention. Teva Pharmaceutical made significant progress in China with AJOVY (fremanezumab), demonstrating efficacy in reducing migraine days, including Phase 3 trial success in the Chinese population.
These companies leverage innovative therapies responding to China's large migraine population, estimated at 65 million, which drives demand. Teva is expanding indications for AJOVY to pediatric use, while AbbVie and Amgen continue to lead with anti-CGRP monoclonal antibodies and Botox. Despite the large patient base, migraine treatment in China often involves NSAIDs due to accessibility and cost, with triptans less used compared to Western countries, highlighting an unmet need for advanced therapies that these multinational companies address with their novel drug launches and clinical progress.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
